广东医学2012，Vol.33Issue(1)：68-71,4.
β地中海贫血对血液透析患者使用重组人促红细胞生成素疗效的影响
Effects of beta-thalassemia minor on the efficacy of erythropoietin in hemodialysis patients
摘要
Abstract
Objective To investigate the effects of beta - thalassemia minor on the efficacy of erythropoietin to ameliorate anemia in hemodialysis patients. Methods The hemodialysis patients with beta - thalassemia minor ( thalasse-mic group ) and the matched hemodialysis patients without beta - thalassemia minor ( control group ) were initially treated with erythropoietin [ 120 ~ 150 IU/( kg · week ) ] subcutaneous injection for three months. After three months of treatment , a high dose of erythropoietin [ 200 ~ 250 IU/( kg · week ) ] was applied for followed three months, if the hemoglobin levels less than 110 g/L in thalassemic group. Results There was no significant difference revealed in baseline hemoglobin level and therapeutic erythropoietin dose between thalassemic group and control group. However, the hemoglobin level of patients in thalassemic group was significantly lower than that in control group at each ends of the three months ( P <0. 01 ). After three months therapy of routine dose erythropoietin, the anemia of patients in control group was corrected. Although hemoglobin level thalassemic group was significantly improved ( P <0. 01 ), the anemia was not corrected. Within the three months of high dose erythropoietin, the hemoglobin level in thalassemic group was significantly increased at the end of the first month ( P <0. 01 ) till the end of the third month when the anemia corrected. The high dose erythropoietin may lead to high blood pressure, but no uncontrolled hypertension, arteriovenous fistula thrombus or other severely adverse events was observed. Conclusion The beta - thalassemia minor reduces the efficacy of erythropoietin in treatment of hemodialysis patients, which could be corrected with a high dose of erythropoietin.关键词
肾透析/促红细胞生成素/地中海贫血Key words
renal dialysis/erythropoietin/thalassemia引用本文复制引用
黄俊,张虹,傅君舟..β地中海贫血对血液透析患者使用重组人促红细胞生成素疗效的影响[J].广东医学,2012,33(1):68-71,4.基金项目
广东省医学科研基金资助项目(编号:A2006495) （编号:A2006495）
